DELRAY BEACH, Fla., July 29, 2005 (PRIMEZONE) -- Hard To Treat Diseases, Incorporated (HTTD) (Pink Sheets:HTDS) announces today that the company has filed a MOTION TO ALTER OR AMEND MEMORANDUM OPINION AND JUDGMENT, OR, IN THE ALTERNATIVE, FOR REHEARING in response to the federal court's final judgment. The motion was submitted to the court on July 28, 2005.
"Although portions of the court's judgment defy common sense, reasonable logic and rational business judgment, HTTD remains confident that the court will correct its judgment on behalf of HTTD's shareholders, instead of rewarding the scheming behavior of individuals that lack credibility," states HTTD's CEO Colm J. King. "The company is continuing to defend its shareholder's rights."
It is the company's policy to post the legal response to the court's final judgment on our Web site as soon as it is filed with the court. Shareholders and investors will be notified by press release.
Complete copies of the motion and court documents can be viewed on the company's Web site at: www.htdsotc.com. Click on 'Corporate,' then click on 'Legal.'
Management's intention and goal with this litigation has been to resolve the current dispute in the most efficient and economical manner in order to provide the maximum benefit to the Company and to HTTD's shareholders.
King states, "HTTD has assets and will continue as a company while attempting to correct the recent judgment. The company's business strategy and plans will be released after the court's ruling regarding HTTD's legal response. HTTD fully intends to become a respected biotech with the intense focus of negotiating a deal with a major biotech/drug company and attaining the goals of benefiting patients and HTTD's shareholders, the real owners of the company."
Cautionary Note Regarding Forward-Looking Statements
The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Certain information included in this news release may contain or constitute forward-looking statements. These forward-looking statements are based on current expectations and are subject to risk and uncertainties. In connection with the "safe harbor" provisions of the Private Securities Litigation Act of 1995, Hard to Treat Diseases, Inc. provides the following cautionary statement identifying important factors which, among others, could cause the actual results or events to differ materially from those set forth or implied by the forward-looking statements and related assumptions.